SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

SCHEDULE OF CONCENTRATION RISK

		For the Year Ended December 31, 2020			For the Year Ended December 31, 2019
	Segment	% of Revenue			% of Revenue
Customer A	Contract Services		*			23	%
Customer B	Regenerative Medicine		13	%		*
Customer C	Contract Services		41	%		*

Concentration of accounts receivable was as follows:

		December 31, 2020			December 31, 2019
	Segment	% of Accounts Receivable			% of Accounts Receivable
Customer B	Regenerative Medicine		14	%		14	%
Customer C	Contract Services		46	%		*
Customer D	Contract Services		*			15	%
Customer E	Regenerative Medicine		*			11	%

SCHEDULE OF REVENUE DISAGGREGATED BY SERVICES AND PRODUCTS

The following table contains revenues as presented in the Consolidated Statements of Operations disaggregated by services and products.

	December 31, 2020		December 31, 2019
Regenerative Medicine
SkinTE Products	$	3,730	$	2,353
Contract Services
Lab Testing Services		4,454		176
Preclinical Research Services		1,942		3,123
		6,396		3,299
Total Net Revenues	$	10,126	$	5,652